Chromatin's rising tide

To capitalize on the full range of possible chromatin targets in and beyond oncology, industry and academia will need to delve deeper into how chromatin regulation is altered in disease, create tools that can reliably validate new targets and develop biomarkers that can improve the chances of success in clinical trials.

A wave of compounds targeting chromatin regulators entered the clinic in 2013, enabled by a decade of progress in understanding how chromatin dysfunction drives cancer.¹...